Pipeline
Inclusive immuno-oncology therapeutics for underserved oncology patients
9Bio is dedicated to advancing immuno-oncology therapeutics, extending the transformative impact of this therapeutic class to a wider spectrum of patients. Our mission encompasses two primary objectives.
Firstly, we strive to address unmet needs in cancer disease indications that, until now, have not benefited from these ground-breaking drugs. These are areas where conventional treatments, primarily surgery and chemotherapy, persist, and five-year survival rates remain constrained.
Secondly, we are committed to expanding the durable use of immuno-oncology therapeutics to patients that are either contraindicated for use or which are commonly required to discontinue use due to complications related to existing comorbidities.
Our dual focus aims to make the powerful benefits immuno-oncology treatments more widely applicable and inclusive across a diverse cancer patient population.
We focus on unlocking the potential of innovative immune modalities, while also leveraging pragmatic value generation of proven therapeutic targets.
Human Health
Novel modality
Target indication: Stomach and esophageal cancers
9B01x is a protein-based immuno-oncology therapeutic designed for treating cancer indications refractory to existing therapies. 9B01x addresses this unmet need via a pioneering mechanism of action which has to date remained underexplored in cancer therapy.
9B01x development is proceeding with the support and expertise of our partners at University of Laval, University of Montreal, TransBIOTech, and the National Research Council Canada (NRC).
Broadening therapeutic access
Target indication: Multiple solid tumor indications
Target indication: Undisclosed Cancer Indications
9B02x aims to deliver the clinical power of immuno-oncology checkpoint inhibitors to cancer patients as an antibody drug conjugate (ADC). This approach targets and destroys both cancer cells and immune-suppressing cells within tumors, while preserving the balance of the immune system in healthy tissues.
9B02x development is proceeding with the support and expertise of private sector partners and our academic and public sector partners at McGill University, Université de Montréal, Université Laval, CERVO, and the National Research Council Canada (NRC).
Reengineering opportunity
Target indication: Undisclosed cancer indications
9B03x is a next generation tumor-targeting antibody drug conjugate (ADC) designed to offer best-in-class safety and tolerability profile to a broad and currently underserved patient population.
9B03x is being developed in collaboration with our partners at the National Research Council Canada (NRC) and the Institute for Research in Immunology and Cancer (IRIC).